2019 Summit
bottom line
-Keynote Speaker-
Celia M. Witten, Deputy Director, Center for Biologics Evaluation and Research, FDA
Timothy Yu, Attending Physician, Division of Genetics and Genomics, Boston Children’s Hospital
bottom line
-Confirmed Speakers-
Cátia Bandeiras, PhD Graduate in Early Health Technology Assessment of Stem Cell Therapies, MIT Portugal Program in Bioengineering
Cullen R. Buie, Associate Professor, Mechanical Engineering, Massachusetts Institute of Technology
Maurizio Cattaneo,
CEO and Founder, Artemis Biosystems
Keen Chung, Principal Scientist, Pall Biotech, Pall Corporation
Dominic Clarke, Global Head of Cell Therapy, HemaCare Corporation
Rena M. Conti, Associate Professor, Markets, Public Policy and Law, Questrom School of Business, Boston University
Robert Deans, Chief of Innovation, BlueRock Therapeutics
Maya Fuerstenau-Sharp, Manager of Segment Marketing, Regenerative Medicine, Sartorius Stedim
Demetrios Kalaitzidis, Director, Immuno-Oncology, CRISPR Therapeutics
Konstantinos Karagiannis, Lead Bioinformatics Engineer, CRISPR Therapeutics
Sadik H. Kassim, Chief Technology Officer, Vor Biopharma
Karen Katz, Director, FoCUS Program, MIT Center for Biomedical Innovation
René Labatut, Vice President, Head of Biologics Technology Innovation Strategy, Sanofi
Christopher Leidel, Head of Acoustic Strategy, Gene Editing and Novel Modalities, MilliporeSigma
Bart Lipkens, Chief Technology Officer, Gene Editing & Novel Modalities, MilliporeSigma
Phillip Maderia, Head of Manufacturing Operations, Codiak BioSciences
John Maga, Senior Director, Process Sciences Purification Process Development, BioMarin
Scott Manalis, Andrew and Erna Viterbi Professor of Biological Engineering, MIT Koch Institute for Integrative Cancer Research
Travis McCready, President and CEO, Massachusetts Life Sciences Center
Jerome Ritz, Executive Director, Connell and O’Reilly Cell Manipulation Core Facility, Dana-Farber Cancer Institute
Jonathan Salcedo, PhD Candidate, University of Southern California; Visiting Scholar, FoCUS Program, MIT Center for Biomedical Innovation
Anthony J. Sinskey, Professor of Biology; Faculty Director, MIT Center for Biomedical Innovation
Stacy Springs, Executive Director, Biomanufacturing Initiatives; Senior Director of Programs, MIT Center for Biomedical Innovation
Jessica Tate, Principal Investigator, Science & Technology, Pharma Services, Viral Vector Services, Thermo Fisher Scientific
Arun Tholudu, Executive Director, Process Development, Amgen
Chelsea Qiong Xue, Head of Analytical Development for Cell Therapies, Takeda
Vijay Yabannavar, Executive Vice President of Manufacturing and Technical Operations, Gritstone Oncology
bottom line

ATMPs such as cell and gene therapies have demonstrated efficacy in indications ranging from oncology to rare genetic diseases. With these demonstrated successes, and with the promise that ATMPs could successfully treat even more common disease indications such as diabetes, the challenge remains of ensuring that these medicines are accessible to the patients who need them.

MIT’s Center for Biomedical Innovation BioMAN Program explores how we can meet the needs of patients by sustaining this vibrant and growing industry sector.

The 2019 BioMAN Summit brings together thought leaders from industry, academia, and government for a series of invited presentations and panel discussions that will:

  • Examine the main factors that will impact widespread adoption of ATMPs, including cost of goods, manufacturing scalability, supply chain issues, and financing, and how innovations in technology and policy can address these challenging issues
  • Identify the advances in analytical technologies needed to increase understanding of ATMP products and processes and how these will improve manufacturing process design and control and increase product quality
  • Investigate how applying technology innovation across the product development lifecycle can increase the probability of successful development and commercialization of these important medicines
  • Discover how the work of MIT scientists and other regional clinicians, researchers, and manufacturers is advancing the state-of-the-art in ATMP science
  • Explore the role of collaboration in accelerating development, manufacturing, and regulatory approval for these novel modalities
bottom line